NLRP3 and Stroke: MCC950, a specific inhibitor of the NLRP3 inflammasome, inhibits NLRP3 activation mainly by interacting with the Walker B motif in the NACHT structural domain of NLRP3 and by affecting the ATP hydrolysis of NLRP3, thereby reducing cell death, and may be considered a candidate for stroke treatment.